BOLT — Bolt Biotherapeutics Share Price
0.000.00%
Last trade - 00:00- $10.75m
- -$28.08m
- $7.69m
- 13
- 50
- 57
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.23 | ||
| Price to Tang. Book | 0.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.96 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -94.12% | ||
| Return on Equity | -83.92% | ||
| Operating Margin | -1870.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.23 | 1.26 | 5.73 | 7.88 | 7.69 | 4.31 | 5.36 | 104.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Directors
- Randall Schatzman CEO (66)
- William Quinn CFO (50)
- David Dornan CSO (43)
- Edith Perez OTH (64)
- Grant Yonehiro OTH (57)
- James Healy LED (55)
- Edgar Engleman IND (75)
- Kathleen Laporte IND (59)
- Frank Lee IND
- Richard Miller IND (69)
- Brian O Callaghan IND
- Nicole Onetto IND (68)
- Mahendra Shah IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 22nd, 2015
- Public Since
- February 5th, 2021
- No. of Shareholders
- 13
- No. of Employees
- 52
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,916,985
- Address
- 900 Chesapeake Drive, REDWOOD CITY, 94063
- Web
- https://boltbio.com/
- Phone
- +1 6506659295
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for BOLT
Q3 2025 Bolt Biotherapeutics Inc Earnings Release
Similar to BOLT
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Bolt Biotherapeutics share price?
As of Today at 19:40 UTC, shares in Bolt Biotherapeutics are trading at $5.61. This share price information is delayed by 15 minutes.
How has the Bolt Biotherapeutics share price performed this year?
Shares in Bolt Biotherapeutics last closed at $5.61 and the price had moved by -62.48% over the past 365 days. In terms of relative price strength the Bolt Biotherapeutics share price has underperformed the S&P500 Index by -66.81% over the past year.
What are the analyst and broker recommendations for Bolt Biotherapeutics?
The overall consensus recommendation for Bolt Biotherapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Bolt Biotherapeutics dividend yield?
Bolt Biotherapeutics does not currently pay a dividend.
Does Bolt Biotherapeutics pay a dividend?
Bolt Biotherapeutics does not currently pay a dividend.
When does Bolt Biotherapeutics next pay dividends?
Bolt Biotherapeutics does not currently pay a dividend.
How do I buy Bolt Biotherapeutics shares?
To buy shares in Bolt Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bolt Biotherapeutics?
As of the previous close price of $5.61, shares in Bolt Biotherapeutics had a market capitalisation of $10.75m.
Where are Bolt Biotherapeutics shares listed?
Here are the trading details for Bolt Biotherapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BOLT
What kind of share is Bolt Biotherapeutics?
Based on an overall assessment of its quality, value and momentum Bolt Biotherapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bolt Biotherapeutics share price forecast for 2025?
The analyst consensus target price for shares in Bolt Biotherapeutics is $40.00. That is 613.01% above the last closing price of $5.61.
Analysts covering Bolt Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$23.53 for the next financial year.
Find out moreWhat is the trend in the Bolt Biotherapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bolt Biotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -48.18%.
As of the last closing price of $5.61, shares in Bolt Biotherapeutics were trading -42.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bolt Biotherapeutics PE Ratio?
The Bolt Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bolt Biotherapeutics?
Bolt Biotherapeutics' management team is headed by:
- Randall Schatzman - CEO
- William Quinn - CFO
- David Dornan - CSO
- Edith Perez - OTH
- Grant Yonehiro - OTH
- James Healy - LED
- Edgar Engleman - IND
- Kathleen Laporte - IND
- Frank Lee - IND
- Richard Miller - IND
- Brian O Callaghan - IND
- Nicole Onetto - IND
- Mahendra Shah - IND